Pharmacokinetics, pharmacodynamics and safety profile of SKB336, a selective inhibitor of coagulation factor XI/XIa in healthy subjects
SKB336 was generally tolerated, without any bleeding events in healthy volunteers. Besides, SKB336 presented a persistent dose-dependent prolongation of APTT and duration of FXI inhibition.
Authors
- Qiufen Xie
- Linyu Cao
- Zhiyan Liu (ORCID: https://orcid.org/0000-0001-9668-7756)
- Nan Zhao (ORCID: https://orcid.org/0000-0002-0854-0007)
- Junyou Ge
- Qian Xiang (ORCID: https://orcid.org/0000-0002-8245-2611)
- Jing Si (ORCID: https://orcid.org/0000-0003-4540-6859)
- Yimin Cui (ORCID: https://orcid.org/0000-0002-4186-1005)
- Yaling Li (ORCID: https://orcid.org/0000-0002-4441-6783)
- Shuang Zhou (ORCID: https://orcid.org/0000-0003-0761-5094)
- Xia Zhao (ORCID: https://orcid.org/0000-0003-2497-3934)
- Qingmei Wu (ORCID: https://orcid.org/0000-0002-9405-897X)
Institutions
- Peking University (CN)
- China National Biotechnology (China) (CN)
- Kelun Group (China) (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1002/bcp.70043
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 1.63